Salicylihalamide A Inhibits the Vo Sector of the V-ATPase through a Mechanism Distinct from Bafilomycin A1

Xiao Song Xie, David Padron, Xibin Liao, Jin Wang, Michael G. Roth, Jef K. De Brabander

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

The newly identified specific V-ATPase inhibitor, salicylihalamide A, is distinct from any previously identified V-ATPase inhibitors in that it inhibits only mammalian V-ATPases, but not those from yeast or other fungi (Boyd, M. R., Farina, C., Belfiore P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., and Bowman, E. J. (2001) J. Pharmacol. Exp. Ther. 297, 114-120). In addition, salicylihalamide A does not compete with concanamycin or bafilomycin for binding to V-ATPase, indicating that it has a different binding site from those classic V-ATPase inhibitors (Huss, M., Ingenhorst, G., Konig, S., Gassel, M., Drose, S., Zeeck, A., Altendorf, K., and Wieczorek, H. (2002) J. Biol. Chem. 277, 40544-40548). By using purified bovine brain V-pump and its dissociated V1 and V0 sectors, we identified the recognition and binding site for salicylihalamide to be within the V0 domain. Salicylihalamide does not inhibit the ATP hydrolysis activity of the dissociated V1-ATPase but inhibits the ATPase activity of the holoenzyme by inhibiting the V0 domain. Salicylihalamide causes a dramatic redistribution of cytosolic V1 from soluble to membrane-associated form, a change not observed in cells treated with either bafilomycin of NH4Cl. By synthesizing and characterizing a series of salicylihalamide derivatives, we investigated the structural determinants of salicylihalamide inhibition in terms of potency and reversibility, and used this information to suggest a possible binding mechanism.

Original languageEnglish (US)
Pages (from-to)19755-19763
Number of pages9
JournalJournal of Biological Chemistry
Volume279
Issue number19
DOIs
StatePublished - May 7 2004

Fingerprint

Adenosine Triphosphatases
Binding Sites
Holoenzymes
bafilomycin A1
salicylihalamide A
Fungi
Yeast
Hydrolysis
Brain
Adenosine Triphosphate
Yeasts
Pumps
Derivatives
Membranes

ASJC Scopus subject areas

  • Biochemistry

Cite this

Salicylihalamide A Inhibits the Vo Sector of the V-ATPase through a Mechanism Distinct from Bafilomycin A1 . / Xie, Xiao Song; Padron, David; Liao, Xibin; Wang, Jin; Roth, Michael G.; De Brabander, Jef K.

In: Journal of Biological Chemistry, Vol. 279, No. 19, 07.05.2004, p. 19755-19763.

Research output: Contribution to journalArticle

@article{ad00aec87a084929b9adcae710d46378,
title = "Salicylihalamide A Inhibits the Vo Sector of the V-ATPase through a Mechanism Distinct from Bafilomycin A1",
abstract = "The newly identified specific V-ATPase inhibitor, salicylihalamide A, is distinct from any previously identified V-ATPase inhibitors in that it inhibits only mammalian V-ATPases, but not those from yeast or other fungi (Boyd, M. R., Farina, C., Belfiore P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., and Bowman, E. J. (2001) J. Pharmacol. Exp. Ther. 297, 114-120). In addition, salicylihalamide A does not compete with concanamycin or bafilomycin for binding to V-ATPase, indicating that it has a different binding site from those classic V-ATPase inhibitors (Huss, M., Ingenhorst, G., Konig, S., Gassel, M., Drose, S., Zeeck, A., Altendorf, K., and Wieczorek, H. (2002) J. Biol. Chem. 277, 40544-40548). By using purified bovine brain V-pump and its dissociated V1 and V0 sectors, we identified the recognition and binding site for salicylihalamide to be within the V0 domain. Salicylihalamide does not inhibit the ATP hydrolysis activity of the dissociated V1-ATPase but inhibits the ATPase activity of the holoenzyme by inhibiting the V0 domain. Salicylihalamide causes a dramatic redistribution of cytosolic V1 from soluble to membrane-associated form, a change not observed in cells treated with either bafilomycin of NH4Cl. By synthesizing and characterizing a series of salicylihalamide derivatives, we investigated the structural determinants of salicylihalamide inhibition in terms of potency and reversibility, and used this information to suggest a possible binding mechanism.",
author = "Xie, {Xiao Song} and David Padron and Xibin Liao and Jin Wang and Roth, {Michael G.} and {De Brabander}, {Jef K.}",
year = "2004",
month = "5",
day = "7",
doi = "10.1074/jbc.M313796200",
language = "English (US)",
volume = "279",
pages = "19755--19763",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "19",

}

TY - JOUR

T1 - Salicylihalamide A Inhibits the Vo Sector of the V-ATPase through a Mechanism Distinct from Bafilomycin A1

AU - Xie, Xiao Song

AU - Padron, David

AU - Liao, Xibin

AU - Wang, Jin

AU - Roth, Michael G.

AU - De Brabander, Jef K.

PY - 2004/5/7

Y1 - 2004/5/7

N2 - The newly identified specific V-ATPase inhibitor, salicylihalamide A, is distinct from any previously identified V-ATPase inhibitors in that it inhibits only mammalian V-ATPases, but not those from yeast or other fungi (Boyd, M. R., Farina, C., Belfiore P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., and Bowman, E. J. (2001) J. Pharmacol. Exp. Ther. 297, 114-120). In addition, salicylihalamide A does not compete with concanamycin or bafilomycin for binding to V-ATPase, indicating that it has a different binding site from those classic V-ATPase inhibitors (Huss, M., Ingenhorst, G., Konig, S., Gassel, M., Drose, S., Zeeck, A., Altendorf, K., and Wieczorek, H. (2002) J. Biol. Chem. 277, 40544-40548). By using purified bovine brain V-pump and its dissociated V1 and V0 sectors, we identified the recognition and binding site for salicylihalamide to be within the V0 domain. Salicylihalamide does not inhibit the ATP hydrolysis activity of the dissociated V1-ATPase but inhibits the ATPase activity of the holoenzyme by inhibiting the V0 domain. Salicylihalamide causes a dramatic redistribution of cytosolic V1 from soluble to membrane-associated form, a change not observed in cells treated with either bafilomycin of NH4Cl. By synthesizing and characterizing a series of salicylihalamide derivatives, we investigated the structural determinants of salicylihalamide inhibition in terms of potency and reversibility, and used this information to suggest a possible binding mechanism.

AB - The newly identified specific V-ATPase inhibitor, salicylihalamide A, is distinct from any previously identified V-ATPase inhibitors in that it inhibits only mammalian V-ATPases, but not those from yeast or other fungi (Boyd, M. R., Farina, C., Belfiore P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., and Bowman, E. J. (2001) J. Pharmacol. Exp. Ther. 297, 114-120). In addition, salicylihalamide A does not compete with concanamycin or bafilomycin for binding to V-ATPase, indicating that it has a different binding site from those classic V-ATPase inhibitors (Huss, M., Ingenhorst, G., Konig, S., Gassel, M., Drose, S., Zeeck, A., Altendorf, K., and Wieczorek, H. (2002) J. Biol. Chem. 277, 40544-40548). By using purified bovine brain V-pump and its dissociated V1 and V0 sectors, we identified the recognition and binding site for salicylihalamide to be within the V0 domain. Salicylihalamide does not inhibit the ATP hydrolysis activity of the dissociated V1-ATPase but inhibits the ATPase activity of the holoenzyme by inhibiting the V0 domain. Salicylihalamide causes a dramatic redistribution of cytosolic V1 from soluble to membrane-associated form, a change not observed in cells treated with either bafilomycin of NH4Cl. By synthesizing and characterizing a series of salicylihalamide derivatives, we investigated the structural determinants of salicylihalamide inhibition in terms of potency and reversibility, and used this information to suggest a possible binding mechanism.

UR - http://www.scopus.com/inward/record.url?scp=2442522365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442522365&partnerID=8YFLogxK

U2 - 10.1074/jbc.M313796200

DO - 10.1074/jbc.M313796200

M3 - Article

C2 - 14998996

AN - SCOPUS:2442522365

VL - 279

SP - 19755

EP - 19763

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 19

ER -